BR112012018843B8 - radioimunoconjugado que se liga a cd37 humano, composição farmacêutica e kit para a produção do radioimunoconjugado - Google Patents

radioimunoconjugado que se liga a cd37 humano, composição farmacêutica e kit para a produção do radioimunoconjugado

Info

Publication number
BR112012018843B8
BR112012018843B8 BR112012018843A BR112012018843A BR112012018843B8 BR 112012018843 B8 BR112012018843 B8 BR 112012018843B8 BR 112012018843 A BR112012018843 A BR 112012018843A BR 112012018843 A BR112012018843 A BR 112012018843A BR 112012018843 B8 BR112012018843 B8 BR 112012018843B8
Authority
BR
Brazil
Prior art keywords
radioimmunoconjugate
binds
human
kit
production
Prior art date
Application number
BR112012018843A
Other languages
English (en)
Other versions
BR112012018843A2 (pt
BR112012018843A8 (pt
BR112012018843B1 (pt
Inventor
Dahle Jostein
S Bruland Oyvind
H Larsen Roy
Original Assignee
Nordic Nanovector As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nordic Nanovector As filed Critical Nordic Nanovector As
Publication of BR112012018843A2 publication Critical patent/BR112012018843A2/pt
Publication of BR112012018843A8 publication Critical patent/BR112012018843A8/pt
Publication of BR112012018843B1 publication Critical patent/BR112012018843B1/pt
Publication of BR112012018843B8 publication Critical patent/BR112012018843B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

radioimunoconjugado que se liga a cd37 humano, composição farmacêutica, uso do radioimunoconjugado, método para tratamento de uma malignidade de célula b e kit para a produção do radioimunoconjugado. a presente invenção refere-se a um radioimunoconjugado que se liga a cd37 humano. as composições farmacêuticas e usos da mesma para o tratamento de câncer- e, em particular, malignidades de célula b - são aspectos da presente invenção.
BR112012018843A 2010-01-29 2011-01-28 radioimunoconjugado que se liga a cd37 humano, composição farmacêutica e kit para a produção do radioimunoconjugado BR112012018843B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29952410P 2010-01-29 2010-01-29
NO20100143 2010-01-29
US61/299,524 2010-01-29
NO20100143A NO331080B1 (no) 2010-01-29 2010-01-29 Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav
PCT/EP2011/051231 WO2011092295A2 (en) 2010-01-29 2011-01-28 Novel radioimmunoconjugates and uses thereof

Publications (4)

Publication Number Publication Date
BR112012018843A2 BR112012018843A2 (pt) 2017-10-17
BR112012018843A8 BR112012018843A8 (pt) 2017-12-19
BR112012018843B1 BR112012018843B1 (pt) 2020-09-24
BR112012018843B8 true BR112012018843B8 (pt) 2020-12-22

Family

ID=44319900

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012018843A BR112012018843B8 (pt) 2010-01-29 2011-01-28 radioimunoconjugado que se liga a cd37 humano, composição farmacêutica e kit para a produção do radioimunoconjugado

Country Status (26)

Country Link
US (2) US8628749B2 (pt)
EP (2) EP2705857B1 (pt)
JP (2) JP5646652B2 (pt)
KR (2) KR101893720B1 (pt)
CN (2) CN104338154B (pt)
AU (1) AU2011209441B2 (pt)
BR (1) BR112012018843B8 (pt)
CA (1) CA2786655C (pt)
DK (2) DK2528627T3 (pt)
ES (2) ES2592402T3 (pt)
HK (2) HK1179157A1 (pt)
HR (1) HRP20140538T1 (pt)
IL (2) IL221091A (pt)
MX (2) MX2012008695A (pt)
NO (1) NO331080B1 (pt)
NZ (1) NZ601055A (pt)
PH (1) PH12017501038A1 (pt)
PL (1) PL2528627T3 (pt)
PT (1) PT2528627E (pt)
RS (1) RS53346B (pt)
RU (2) RU2560587C9 (pt)
SG (1) SG182685A1 (pt)
SI (1) SI2528627T1 (pt)
UA (1) UA108631C2 (pt)
WO (1) WO2011092295A2 (pt)
ZA (1) ZA201205007B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2658438C2 (ru) * 2011-12-13 2018-06-21 Нордик Нановектор Аса Химерное терапевтическое антитело нн1 против cd-37
MX2014011745A (es) * 2012-03-30 2015-01-22 Immunogen Inc Metodos para aumentar la eficacia de terapia basada en cd37.
CN103933575B (zh) * 2013-01-23 2017-09-29 上海新理念生物医药科技有限公司 一种三齿型连接子及其应用
BR112015030457A2 (pt) * 2013-06-07 2017-08-22 Nordic Nanovector As Método para regular positivamente a expressão de antígeno
JP6510518B2 (ja) * 2013-08-01 2019-05-08 アジェンシス，インコーポレイテッド Ｃｄ３７タンパク質に結合する抗体薬物結合体（ａｄｃ）
CN107735110B (zh) * 2015-04-07 2021-11-26 纪念斯隆-凯特琳癌症中心 纳米粒子免疫偶联物
GB201600328D0 (en) * 2016-01-08 2016-02-24 Univ Oslo Hf Anti-CD37 chimeric antigen receptors and immune cells expressing them
AU2017327772A1 (en) * 2016-09-16 2019-03-21 Nordic Nanovector Asa Treatment of Non-Hodgkin lymphoma using lilotomab and 177Lu-lilotomab satetraxetan
KR102406510B1 (ko) 2017-07-03 2022-06-10 현대자동차주식회사 연료전지 시스템용 수소 공급 방법
CN109550061A (zh) * 2017-09-26 2019-04-02 南京江原安迪科正电子研究发展有限公司 一种用于放射性核素标记抗体的试剂盒及应用
WO2019101789A1 (en) * 2017-11-22 2019-05-31 Nordic Nanovector Asa Radioimmunoconjugates in combination with other drugs as treatment against nhl
WO2023057595A1 (en) 2021-10-06 2023-04-13 Nordic Nanovector Asa Humanized hh1 rew
EP4412715A1 (en) 2021-10-06 2024-08-14 Nordic Nanovector ASA Humanized hh1
CN114081969A (zh) * 2021-11-23 2022-02-25 成都纽瑞特医疗科技股份有限公司 标记的小分子抗体、及其标记方法和应用
CN117285631A (zh) * 2023-11-24 2023-12-26 原子高科股份有限公司 用于放射性免疫治疗的Lu-177标记MUC1抗体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
WO2001080884A1 (en) * 2000-04-25 2001-11-01 Idec Pharmaceuticals Corporation Intrathecal administration of rituximab for treatment of central nervous system lymphomas
WO2004054615A1 (en) * 2002-12-13 2004-07-01 Mitra Medical Technology Ab Antilymphoma targeting agents with effector and affinity functions linked by a trifunctional reagent
US7534427B2 (en) * 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
US7534431B2 (en) * 2003-01-31 2009-05-19 Immunomedics, Inc. Methods and compositions for administering therapeutic and diagnostic agents
JP4912153B2 (ja) * 2003-12-01 2012-04-11 イミューノメディクス、インコーポレイテッド タンパク質とキレート剤とのコンジュゲートを調製するための改良された方法
SI1912675T1 (sl) * 2005-07-25 2014-07-31 Emergent Product Development Seattle, Llc zmanjšanje števila celic B z uporabo molekul, ki se specifično vežejo na CD37 in CD20
PE20140196A1 (es) * 2007-08-09 2014-03-19 Boehringer Ingelheim Int Anticuerpos anti-cd37

Also Published As

Publication number Publication date
EP2705857A3 (en) 2014-07-30
US8628749B2 (en) 2014-01-14
JP5855209B2 (ja) 2016-02-09
ZA201205007B (en) 2013-09-25
KR20170084349A (ko) 2017-07-19
JP2013518086A (ja) 2013-05-20
HK1179157A1 (en) 2013-09-27
ES2592402T3 (es) 2016-11-30
HK1195736A1 (zh) 2014-11-21
MX342539B (es) 2016-10-04
EP2705857B1 (en) 2016-06-22
RU2012135430A (ru) 2014-03-10
BR112012018843A2 (pt) 2017-10-17
CA2786655C (en) 2016-12-13
IL237507A0 (en) 2015-04-30
DK2705857T3 (en) 2016-08-29
CN104338154B (zh) 2017-09-22
PH12017501038B1 (en) 2017-12-11
CN102762230A (zh) 2012-10-31
WO2011092295A3 (en) 2011-11-24
NZ601055A (en) 2013-12-20
RU2560587C2 (ru) 2015-08-20
PH12017501038A1 (en) 2017-12-11
RU2560587C9 (ru) 2015-11-27
RS53346B (en) 2014-10-31
CN104338154A (zh) 2015-02-11
ES2469140T3 (es) 2014-06-17
CA2786655A1 (en) 2011-08-04
KR101893720B1 (ko) 2018-08-30
AU2011209441A1 (en) 2012-07-19
US9358309B2 (en) 2016-06-07
UA108631C2 (xx) 2015-05-25
PT2528627E (pt) 2014-06-12
US20140147384A1 (en) 2014-05-29
NO331080B1 (no) 2011-09-26
CN102762230B (zh) 2014-08-13
KR101758409B1 (ko) 2017-07-14
PL2528627T3 (pl) 2014-08-29
JP5646652B2 (ja) 2014-12-24
NO20100143A1 (no) 2011-08-01
RU2664475C1 (ru) 2018-08-17
SG182685A1 (en) 2012-08-30
HRP20140538T1 (hr) 2014-07-18
EP2705857A2 (en) 2014-03-12
BR112012018843A8 (pt) 2017-12-19
JP2015057415A (ja) 2015-03-26
WO2011092295A2 (en) 2011-08-04
US20120301396A1 (en) 2012-11-29
IL221091A0 (en) 2012-09-24
BR112012018843B1 (pt) 2020-09-24
EP2528627B1 (en) 2014-03-19
MX2012008695A (es) 2012-11-23
KR20130028051A (ko) 2013-03-18
SI2528627T1 (sl) 2014-08-29
DK2528627T3 (da) 2014-05-12
EP2528627A2 (en) 2012-12-05
IL221091A (en) 2015-03-31
AU2011209441B2 (en) 2016-03-03

Similar Documents

Publication Publication Date Title
BR112012018843B8 (pt) radioimunoconjugado que se liga a cd37 humano, composição farmacêutica e kit para a produção do radioimunoconjugado
UY32427A (es) Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
BR112015023001A2 (pt) composição de salto de exon para tratamento de distrofia muscular
ECSP14017269A (es) Compuestos para tratar la atrofia muscular espinal
BR112013022927A2 (pt) composição, métodos para substituir ou suplementar ou modificar uma microbiota do cólon de um sujeito, e para tratar um sujeito, e, uso de uma composição
BRPI0905733B8 (pt) composição, formulação farmacêutica, método para a produção de uma composição farmacêutica e uso de uma formulação farmacêutica
BR112012008854A2 (pt) combinação, kit de combinação, uso de uma combinação, composição farmacêutica, e, método para tratar câncer em um ser humano
BR112014021531A2 (pt) composto, composição farmacêutica e usos dos mesmos
CR20110466A (es) Anticuerpos biespecíficos anti-erbb-3/anti-c-met
GB201118656D0 (en) New compounds
UY32456A (es) Composicion famaceutica, forma farmaceutica, procedimiento para su preparación, metodos de tratamiento
BR112014021104A2 (pt) métodos e composições para o tratamento da doença de huntington
CO6511271A2 (es) Compuestos de imidazopiridinil-aminopiridina sustituida
MX343135B (es) Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.
BRPI0916286B8 (pt) amidofenóxi-indazóis úteis como inibidores de c-met, seus usos, e composição farmacêutica
PH12013502565A1 (en) Substituted imidazopyridinyl-aminopyridine compounds
EA201591178A1 (ru) Улучшенные композиции для пропускания экзона для лечения мышечной дистрофии
BR112012016129A2 (pt) composto, composição, e, métodos para inibir a atividade de c-met, e para tratar câncer
BRPI0618577A8 (pt) Usos de rituximab
BR112014010290B8 (pt) Composição farmacêutica na forma de dispersão sólida de ativos específicos em polímeros específicos e uso da composição farmacêutica
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
CR20130602A (es) Compuestos novedosos como inhibidores de diacilglicerol aciltransferasa
BR112015017241A8 (pt) composto, composição farmacêutica, uso do composto e da composição farmacêutica e kit
BR112012022337A2 (pt) composição e respectivos método de preparação e uso de quantidade eficaz
BR112014027047A2 (pt) nova formulação

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B65X Notification of requirement for priority examination of patent application
B65Y Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/01/2011, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2594 DE 24/09/2020 QUANTO AO TITULO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 13A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2759 DE 21-11-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.